We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Proteros and Institut Pasteur Korea Establish Discovery Services Collaboration in the Field of Infectious Diseases
News

Proteros and Institut Pasteur Korea Establish Discovery Services Collaboration in the Field of Infectious Diseases

Proteros and Institut Pasteur Korea Establish Discovery Services Collaboration in the Field of Infectious Diseases
News

Proteros and Institut Pasteur Korea Establish Discovery Services Collaboration in the Field of Infectious Diseases

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Proteros and Institut Pasteur Korea Establish Discovery Services Collaboration in the Field of Infectious Diseases"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Proteros Biostructures GmbH (Proteros) has announced that it has entered into a service agreement with Institut Pasteur Korea (IP-K) under which Proteros will provide structure-based drug discovery services to IP-K.

Under this collaboration Proteros will apply its know-how, experience of structural analysis and its proprietary X-ray crystallography platform to support IP-K’s mission to develop therapeutics for infectious diseases.

Cony D’Cruz, Chief Business Officer of Proteros, stated, “Institut Pasteur Korea is a world class translational research institute, renowned as a centre of excellence in biomedical research and technology development with a clear focus on infectious and neglected disease. We welcome the opportunity for Proteros to contribute to these efforts.”

Dr. Michel Liuzzi, Director, Early Discovery Program at IP-K, added “We are very pleased with the expertise and know-how of Proteros in providing timely X-ray crystallography support to our in-house drug discovery projects and we look forward to continue collaborating with Proteros in the future.”

Advertisement